Viatris Readies Landmark Botox Biosimilar, Clinical Trial Coming In H1 2024
Key IND Filing With USFDA Planned For Year-End; Launch In 2026 Slated
Viatris has provided the latest on plans to bring a biosimilar to the world-renowned Botox cosmetic and therapeutic brand, while also discussing other opportunities on the slate, including its pipeline of complex injectables.
You may also be interested in...
Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.
Rajiv Malik is to retire as president of Viatris from 1 April 2024, amid a continuing strategic transformation for the business that was formed by the merger of Mylan and Pfizer’s Upjohn.
Viatris and Mapi have moved a step closer to realizing the US launch of their 505(b)(2) once-